Elotuzumab
Elotuzumab (HuLuc 63) is an IgG1 monoclonal antibody targeting the SLAMF7 receptor. Elotuzumab exerts antitumor activity by activating natural killer cells and inducing antibody-dependent cell-mediated cytotoxicity. Elotuzumab can be combined with Lenalidomide , Dexamethasone (HY-14648), etc., for the research of tumors such as multiple myeloma[1][2].
Product Specifications
CAS Number
915296-00-3
Product Name Alternative
HuLuc 63; PDL 063; BMS 901608
UNSPSC
12352203
Target
Transmembrane Glycoprotein
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/elotuzumab.html
Purity
99.9
Solubility
H2O
Smiles
[Elotuzumab]
Molecular Weight
(145.44 kDa)
References & Citations
[1]Magen H, et al. Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment. Ther Adv Hematol. 2016;7 (4) :187-195.|[2]Bezman NA, et al. PD-1 blockade enhances elotuzumab efficacy in mouse tumor models. Blood Adv. 2017 May 8;1 (12) :753-765.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
HA750591 100 µL
Histone H2A (acetyl K9) Recombinant Rabbit monoclonal Antibody
Sign In for Pricing
View Details 
